Tyra Biosciences, Inc. Financing Cash Flow
Tyra Biosciences, Inc. (TYRA) reported Financing Cash Flow of $162.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.10M, a 260.55% increase year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $160.38M, a 7233.47% increase year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.68M, a 563.31% increase year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $647.00K, a 12.92% decline year-over-year.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $8.10M, a 95.99% decline from fiscal 2024.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $202.14M, a 13051.40% increase from fiscal 2023.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.54M, a 143.20% increase from fiscal 2022.
- Tyra Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $632.00K, a 99.80% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $162.49M 10-Q · filed 2026-08-04 | $167.17M derived: sum of 3 quarters · filed 2026-08-04 | $167.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $160.38M 10-Q · filed 2026-05-13 | $165.07M derived: sum of 2 quarters · filed 2026-05-13 | $165.71M derived: sum of 3 quarters · filed 2026-05-13 | $166.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.33M derived: sum of 2 quarters · filed 2026-03-02 | $5.91M derived: sum of 3 quarters · filed 2026-08-04 | $8.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.23M derived: sum of 2 quarters · filed 2026-08-04 | $3.42M 10-Q · filed 2025-11-05 | $4.12M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $583.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.77M 10-Q · filed 2026-08-04 | $3.48M derived: sum of 3 quarters · filed 2026-08-04 | $4.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.19M 10-Q · filed 2026-05-13 | $2.89M derived: sum of 2 quarters · filed 2026-05-13 | $3.64M derived: sum of 3 quarters · filed 2026-05-13 | $4.01M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $706.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.45M derived: sum of 2 quarters · filed 2026-03-02 | $1.82M derived: sum of 3 quarters · filed 2026-03-02 | $202.14M 10-K · filed 2026-03-02 |
| 2024-09-30 | $743.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.12M derived: sum of 2 quarters · filed 2025-11-05 | $201.43M 10-Q · filed 2025-11-05 | $201.75M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $373.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $200.69M 10-Q · filed 2025-08-14 | $201.01M derived: sum of 3 quarters · filed 2025-08-14 | $201.48M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $200.31M 10-Q · filed 2025-05-08 | $200.64M derived: sum of 2 quarters · filed 2025-05-08 | $201.11M derived: sum of 3 quarters · filed 2025-05-08 | $201.48M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $791.00K derived: sum of 2 quarters · filed 2025-03-27 | $1.16M derived: sum of 3 quarters · filed 2025-03-27 | $1.54M 10-K · filed 2025-03-27 |
| 2023-09-30 | $467.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $837.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.21M 10-Q · filed 2024-11-07 | $1.22M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $370.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $746.00K 10-Q · filed 2024-08-07 | $749.00K derived: sum of 3 quarters · filed 2024-08-07 | $1.11M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $376.00K 10-Q · filed 2024-05-09 | $379.00K derived: sum of 2 quarters · filed 2024-05-09 | $743.00K derived: sum of 3 quarters · filed 2024-05-09 | $770.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $367.00K derived: sum of 2 quarters · filed 2024-03-19 | $394.00K derived: sum of 3 quarters · filed 2024-03-19 | $632.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $391.00K derived: sum of 2 quarters · filed 2023-11-07 | $629.00K 10-Q · filed 2023-11-07 | -$879.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $265.00K 10-Q · filed 2023-08-10 | -$1.24M derived: sum of 3 quarters · filed 2023-08-10 | $182.19M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $238.00K 10-Q · filed 2023-05-04 | -$1.27M derived: sum of 2 quarters · filed 2023-05-04 | $182.17M derived: sum of 3 quarters · filed 2023-05-04 | $181.43M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $181.93M derived: sum of 2 quarters · filed 2023-03-22 | $181.20M derived: sum of 3 quarters · filed 2023-03-22 | $311.35M 10-K · filed 2023-03-22 |
| 2021-09-30 | $183.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $182.70M derived: sum of 2 quarters · filed 2022-11-03 | $312.86M 10-Q · filed 2022-11-03 | $312.85M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$733.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $129.42M 10-Q · filed 2022-08-04 | $129.41M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $130.15M 10-Q · filed 2022-05-05 | $130.15M derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $23.43M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | $23.44M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |